Legend Biotech Corporation

NasdaqGS:LEGN Stock Report

Market Cap: US$9.2b

Legend Biotech Valuation

Is LEGN undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

4/6

Valuation Score 4/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of LEGN when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: LEGN ($50) is trading below our estimate of fair value ($241.71)

Significantly Below Fair Value: LEGN is trading below fair value by more than 20%.


Key Valuation Metric

Which metric is best to use when looking at relative valuation for LEGN?

Other financial metrics that can be useful for relative valuation.

LEGN key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue18.1x
Enterprise Value/EBITDA-22.8x
PEG Ration/a

Price to Sales Ratio vs Peers

How does LEGN's PS Ratio compare to its peers?

The above table shows the PS ratio for LEGN vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average26.2x
ROIV Roivant Sciences
55.6x48.7%US$8.8b
SRPT Sarepta Therapeutics
7.9x23.6%US$11.9b
ADMA ADMA Biologics
12.1x13.5%US$4.0b
IMGN ImmunoGen
29.1x26.0%US$8.4b
LEGN Legend Biotech
20.2x35.1%US$9.2b

Price-To-Sales vs Peers: LEGN is good value based on its Price-To-Sales Ratio (20.2x) compared to the peer average (26.2x).


Price to Earnings Ratio vs Industry

How does LEGN's PE Ratio compare vs other companies in the US Biotechs Industry?

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
Industry Avg.n/a28.3%
n/an/an/a
No. of CompaniesPS048121620

Fetching data

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
Industry Avg.n/a28.3%
n/an/an/a
No more companies

Price-To-Sales vs Industry: LEGN is expensive based on its Price-To-Sales Ratio (20.2x) compared to the US Biotechs industry average (12x).


Price to Sales Ratio vs Fair Ratio

What is LEGN's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

LEGN PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio20.2x
Fair PS Ratio6.7x

Price-To-Sales vs Fair Ratio: LEGN is expensive based on its Price-To-Sales Ratio (20.2x) compared to the estimated Fair Price-To-Sales Ratio (6.7x).


Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst LEGN forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentUS$50.00
US$83.14
+66.3%
11.4%US$95.00US$60.00n/a20
Oct ’25US$47.48
US$82.98
+74.8%
11.7%US$95.00US$60.00n/a19
Sep ’25US$57.55
US$82.93
+44.1%
11.7%US$95.00US$60.00n/a19
Aug ’25US$55.00
US$82.63
+50.2%
12.2%US$95.00US$60.00n/a19
Jul ’25US$46.02
US$82.50
+79.3%
12.2%US$95.00US$60.00n/a19
Jun ’25US$40.01
US$83.03
+107.5%
12.0%US$95.00US$60.00n/a18
May ’25US$43.98
US$86.33
+96.3%
7.9%US$95.00US$65.00n/a18
Apr ’25US$57.22
US$86.45
+51.1%
7.9%US$95.00US$65.00n/a17
Mar ’25US$65.53
US$86.29
+31.7%
9.3%US$100.00US$65.00n/a15
Feb ’25US$56.22
US$86.29
+53.5%
9.3%US$100.00US$65.00n/a15
Jan ’25US$60.17
US$86.57
+43.9%
9.2%US$100.00US$65.00n/a15
Dec ’24US$59.99
US$87.69
+46.2%
6.5%US$100.00US$76.00n/a14
Nov ’24US$66.81
US$87.67
+31.2%
7.0%US$100.00US$76.00n/a12
Oct ’24US$67.17
US$88.18
+31.3%
6.7%US$100.00US$76.00US$47.4811
Sep ’24US$71.59
US$88.18
+23.2%
6.7%US$100.00US$76.00US$57.5511
Aug ’24US$74.62
US$86.70
+16.2%
5.7%US$93.00US$76.00US$55.0010
Jul ’24US$69.03
US$82.50
+19.5%
8.7%US$90.00US$65.00US$46.0210
Jun ’24US$63.62
US$80.82
+27.0%
8.3%US$90.00US$65.00US$40.0111
May ’24US$67.24
US$76.30
+13.5%
9.7%US$90.00US$65.00US$43.9810
Apr ’24US$48.22
US$72.91
+51.2%
9.3%US$87.00US$65.00US$57.2211
Mar ’24US$47.15
US$73.67
+56.2%
9.7%US$87.00US$65.00US$65.539
Feb ’24US$51.80
US$73.67
+42.2%
9.7%US$87.00US$65.00US$56.229
Jan ’24US$49.92
US$68.89
+38.0%
11.8%US$79.00US$53.00US$60.179
Dec ’23US$49.77
US$68.00
+36.6%
12.3%US$79.00US$53.00US$59.998
Nov ’23US$51.01
US$68.00
+33.3%
12.3%US$79.00US$53.00US$66.818
Oct ’23US$40.80
US$68.13
+67.0%
11.4%US$77.00US$53.00US$67.178

Analyst Forecast: Target price is more than 20% higher than the current share price and analysts are within a statistically confident range of agreement.


Discover undervalued companies